The Conversation (0)
Heat Biologics announced it will hold a Type C meeting with the US Food and Drug Administration for the roadmap of their non-small cell lung cancer trial.
Heat Biologics (NASDAQ:HTBX) announced it will hold a Type C meeting with the US Food and Drug Administration for the roadmap of their non-small cell lung cancer trial.
As quoted in the press release:
“We are looking forward to discussing our proposed HS-110 registrational pathway and development plan for the treatment of advanced NSCLC,” said Jeff Wolf, CEO of Heat. “We are encouraged by the positive safety and efficacy signals that have been previously reported, which support the hypothesis that tumor-specific T-cell activation enhances the clinical activity of checkpoint inhibitor therapy. We are adapting to the changing landscape of cancer immunotherapy by incorporating novel combinations, and very much look forward to progressing our study.”
Click here to read the full press release.
Source: www.accesswire.com
